RecruitingNot ApplicableNCT07801638

Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis

Sponsor

Capital Medical University

Enrollment

80 participants

Start Date

Mar 1, 2025

Study Type

INTERVENTIONAL

Conditions

Cerebral Venous Thrombosis

Summary

This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with acute cerebral venous thrombosis (CVT).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Standard Treatment and a drug called Tocilizumab for people with cerebral venous thrombosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTocilizumab

Tocilizumab 240 mg will be diluted with 0.9% sodium chloride to a total volume of 100 mL and administered as a single intravenous infusion over more than 1 hour.

DRUGStandard Treatment

Participants will receive guideline-recommended standard treatment plus a single intravenous infusion of placebo.

Locations(1)

Xuanwu Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07801638

Related Trials

Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis

NCT073523581 location

Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam

NCT070836091 location

Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients

NCT069477071 location

Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis

NCT065311221 location

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

NCT046607471 location